Scientific Presentations for Products in Development
Clovis Oncology presents data on its products in development at a variety of medical conferences. Our current and historic presentations are provided in the following links.
To view Encore Presentations, visit our Encore Presentations Page.
Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy
Oral presentation at 2023 ASCO Genitourinary Cancers Symposium
TRITON3: A Phase 3 Study of Rucaparib vs Physician’s Choice of Therapy in Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Deficiency
Oral Presentation 2022 PCF Annual Retreat
Overall Survival Results From ARIEL3: A Phase 3 Randomised, Double-blind Study of Rucaparib vs Placebo Following Response to Platinum-Based Chemotherapy for Recurrent Ovarian Carcinoma
Oral Presentation 2022 ESGO Congress
<sup>177</sup>Lu-FAP-2286 in patients with advanced or metastatic solid tumours: updated data from a phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumour activity (LuMIERE)
Oral Presentation 2022 EANM Annual Congress
Real-world Progression-Free Survival and Overall Survival for Patients With Advanced Ovarian Cancer Utilizing PARP Inhibitor Second-line Maintenance Therapy vs Active Surveillance
ePoster Presentation 2022 IGCS Annual Global Meeting
Overall Survival Results From ARIEL3: A Phase 3 Randomised, Double-blind Study of Rucaparib Vs Placebo Following Response to Platinum-Based Chemotherapy for Recurrent Ovarian Carcinoma
Oral Presentation 2022 IGCS Annual Global Meeting
Rucaparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer: Defining Benefit According to Disease Risk Subgroups Within the Phase 3 ATHENA–MONO Study
Oral Presentation 2022 ESMO Congress
Overall Survival Results From ARIEL4: A Phase 3 Study Assessing Rucaparib vs Chemotherapy in Patients With Advanced, Relapsed Ovarian Carcinoma and a Deleterious <i>BRCA1/2</i> Mutation
Oral Presentation 2022 ESMO Congress
First-in-human evaluation of <sup>68</sup>Ga-FAP-2286, a fibroblast activation protein targeted radioligand
Oral Presentation 2022 SNMMI Annual Meeting
<sup>177</sup>Lu-FAP-2286 in patients with advanced or metastatic solid tumors: initial data from a phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity (LuMIERE)
Oral Presentation 2022 SNMMI Annual Meeting
ATHENA–MONO (GOG-3020/ENGOT-ov45): A Randomized, Double-blind, Phase 3 Trial Evaluating Rucaparib Monotherapy Vs Placebo As Maintenance Treatment Following Response to First-line Platinum-based Chemotherapy In Ovarian Cancer
Oral Presentation 2022 ASCO Annual Meeting
Imaging of Solid Tumors Using <sup>68</sup>Ga-FAP-2286
Poster Presentation 2022 ASCO Annual Meeting
Efficacy and Safety of Rucaparib Maintenance Treatment in Patients From ARIEL3 With Platinum-Sensitive, Recurrent Ovarian Carcinoma Not Associated With Homologous Recombination Deficiency
Poster Presentation 2022 ASCO Annual Meeting
Efficacy and Safety of Lucitanib + Nivolumab in Patients With Advanced Gynecologic Malignancies: Phase 2 Results From the LIO-1 Study (NCT04042116; ENGOT-GYN3/AGO/LIO)
Poster Presentation 2022 ASCO Annual Meeting
Comparative Biodistribution and Radiotherapeutic Efficacy of the Fibroblast Activation Protein (FAP)-Targeting Agents FAP-2286 and FAPI-46
Poster Presentation 2022 AACR Annual Meeting
LuMIERE: A Phase 1/2 Study Investigating Safety, Pharmacokinetics, Dosimetry, and Preliminary Antitumor Activity of <sup>177</sup>Lu-FAP-2286 in Patients With Advanced or Metastatic Solid Tumors
Poster Presentation 2022 AACR Annual Meeting
Nonclinical Evaluation of Rucaparib in Tumors with Mutations in Non-<i>BRCA1/2</i> Homologous Recombination Repair (HRR) genes
Poster Presentation 2022 AACR Annual Meeting
LIO-1: Initial Phase 2 Experience of Lucitanib + Nivolumab in Patients With Metastatic or Recurrent Cervical Cancer (NCT04042116; ENGOT-GYN3/AGO/LIO)
Oral Presentation 2022 SGO Annual Meeting
